PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF

4830 reported adverse events

Drug classes: Endoglycosidase [EPC] HER2/neu Receptor Antagonist [EPC]

These side effects are most commonly reported by patients taking PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF:

# Side effect Count
0 NO ADVERSE EVENT 912
1 OFF LABEL USE 902
2 DIARRHOEA 432
3 INJECTION SITE PAIN 213
4 PAIN 212
5 DEATH 164
6 FATIGUE 163
7 INJECTION SITE REACTION 162
8 PYREXIA 157
9 DISEASE PROGRESSION 142
See all common reactions for PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF

PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 MODIFIED RADICAL MASTECTOMY 19 0.3276
1 AXILLARY LYMPHADENECTOMY 16 0.2051
2 ACUTE NECROTISING ENCEPHALOPATHY 1 0.1667
3 POLYNEUROPATHY CHRONIC 7 0.1029
4 HORMONE RECEPTOR NEGATIVE HER2 POSITIVE BREAST CANCER 1 0.0909
5 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR POSITIVE 1 0.0833
6 INCISION SITE DISCOMFORT 1 0.0714
7 ADMINISTRATION SITE REACTION 26 0.0674
8 DIABETIC DERMOPATHY 1 0.0625
9 BREAST OPERATION 34 0.0416
See all enriched reactions for PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF